News

Zacks Investment Research on MSN14d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...
MyChesCo on MSN8d
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer
AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...
Business Wire15d
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...
Fierce Pharma4d
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer
Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...
Pharmabiz10d
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
Medical Dialogues10h
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib
Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...
Seeking Alpha5d
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
The approval of Imfinzi was granted based on results from the pivotal ADRIATIC Phase III trial which demonstrated statistically significant and clinically meaningful results for its dual primary ...
Benzinga.com29d
Eventful Monday For AstraZeneca - What's Going On?
The EU approved AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, reducing the risk of death by 27% in ADRIATIC Phase 3 trial. With stocks plunging, steady income is key.
Yahoo Finance8d
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC) in adults. NSCLC is the most prevalent form ...
AstraZeneca’s Imfinzi combination with chemo approved in EU to treat NSCLC
Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...
Yahoo Finance14d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as ...